Dr Johnny C Moreno, MD in Artesia, NM - General Practice

Dr Johnny C Moreno, MD is a General Practice physician based in Artesia, New Mexico. Dr Johnny C Moreno is licensed to practice in New Mexico (license number 80-218) and his current practice location is 606 N 13th St, Artesia, New Mexico. He can be reached at his office (for appointments etc.) via phone at (575) 748-1266.

NPI number for Dr Johnny C Moreno is 1871591701 and his current mailing address is 606 N 13th St, Artesia, New Mexico. He does not participate in medicare program and thus does not accept medicare assignments. His NPI Number is 1871591701.

Contact Information

	Dr Johnny C Moreno, MD
	606 N 13th St, Artesia, NM 88210-1165
	(575) 748-1266
	(575) 748-8822

Physician's Profile

Full Name	Dr Johnny C Moreno
Gender	Male
Speciality	General Practice
Location	606 N 13th St, Artesia, New Mexico
Accepts Medicare Assignments	Does not participate in Medicare Program. He may not accept medicare assignment.

NPI Data:

NPI Number: 1871591701
Provider Enumeration Date: 07/13/2005
Last Update Date: 12/30/2011

Medical Identifiers

Medical identifiers for Dr Johnny C Moreno such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1871591701	NPI	-	NPPES

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
208D00000X	General Practice	80-218 (New Mexico)	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Dr Johnny C Moreno is NOT enrolled with medicare and thus cannot prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Dr Johnny C Moreno, MD 606 N 13th St, Artesia, NM 88210-1165 Ph: (575) 748-1266	Dr Johnny C Moreno, MD 606 N 13th St, Artesia, NM 88210-1165 Ph: (575) 748-1266

News Archive

BioLineRx announces regulatory submissions to commence Phase 1/2 trial for treatment of celiac disease

BioLineRx, a biopharmaceutical development company, announced today that it has filed the necessary regulatory submissions to commence a Phase 1/2 trial for BL-7010 - for the treatment of celiac disease - with the Finnish National Supervisory Authority for Welfare and Health (Valvira). The relevant ethics committee has already approved commencement of the study.

OPKO reports more than 50% enrollment in phase 3 trial of Rayaldy for treatment of secondary hyperparathyroidism

OPKO Health, Inc., has surpassed 50% enrollment in the first phase 3 trial of RayaldyTM to treat patients with secondary hyperparathyroidism (SHPT), stage 3 or 4 chronic kidney disease (CKD) and vitamin D insufficiency.

Internet-based surveillance helps confront infectious disease threats at mass gatherings

Integrating real-time Internet-based infectious disease surveillance with knowledge of worldwide air traffic patterns could help in confronting infectious disease threats at mass gatherings, such as the Olympics and other large scale events, suggests an article in CMAJ.

Phase 2 clinical study of PEG-Interferon lambda commenced

ZymoGenetics, Inc. today announced the initiation of a Phase 2 clinical trial of PEG-Interferon lambda (IL-29) and ribavirin in treatment-naïve patients with chronic hepatitis C virus (HCV) infection (the "EMERGE" study).

Dr Johnny C Moreno, MD - General Practice in Artesia, NM